PharmaShots

MAY 12, 2023

Sanofi Reports P-IIIb Trial (HARMONIE) Results of Nirsevimab for the Prevention of Hospitalizations due to RSV-Related LRTD Date: May 12, 2023 | Tags: Sanofi, Nirsevimab, RSV-Related LRTD, Clinical Trial, P-IIIb, HARMONIE Trial G1 Therapeutics Presents Preliminary Results from P-II Trial of Trilaciclib for Triple-Negative Breast Cancer at ESMO 2023 (..)

FDA 40

FDA Chemotherapy Immunization Hospitals 40

PharmaShots

MAY 26, 2023

Takeda and HUTCHMED's Fruquintinib Receives Priority Review from the US FDA to Treat Metastatic Colorectal Cancer Date: May 26, 2023 | Tags: Takeda, HUTCHMED, Fruquintinib, Metastatic Colorectal Cancer, Regulatory, Priority Review, US, FDA Gilead Receives EMA’s CHMP Positive Opinion to Extend the Use of Veklury (remdesivir) for COVID-19 Date: (..)

FDA 40

FDA 40

PharmaShots

APRIL 14, 2023

Ocugen Reports Preliminary Results from the P-I/II Trial of OCU400 for the Treatment of Retinitis Pigmentosa and Leber Congenital Amaurosis Date: Apr 14, 2023 | Tags: Ocugen, OCU400, Retinitis Pigmentosa, Leber Congenital Amaurosis, Clinical Trial, P-I/II Trial Candesant Biomedical Receives the US FDA Clearance of Brella SweatControl Patch for Primary (..)

FDA 40

FDA 40

PharmaShots

MARCH 31, 2023

PDS Biotech to Initiate P-III Trial (VERSATILE-003) of PDS0101 + Keytruda (pembrolizumab) for Head and Neck Cancer Date: Mar 31, 2023 | Tags: PDS Biotech, PDS0101, Keytruda, pembrolizumab, Head, Neck Cancer, Clinical Trial, P-III, VERSATILE-003 Trial Omega Therapeutics Entered into a Clinical Supply Agreement with Roche to Evaluate OTX-2002 for Hepatocellular (..)

FDA 40

FDA 40

PharmaShots

MARCH 24, 2023

PTC Therapeutics’ Upstaza (eladocagene exuparvovec) Receives NICE Recommendation for the Treatment of AADC Deficiency Date: Mar 24, 2023 | Tags: PTC Therapeutics, Upstaza, eladocagene exuparvovec, AADC Deficiency, Regulatory, NICE Onconova Therapeutics Entered into a Research Collaboration with Pangea Biomed to Identify Biomarkers for Cancer (..)

FDA 40

FDA Immunization 40

The Checkup by Singlecare

DECEMBER 5, 2023

The #ozempic tag on TikTok has amassed over 1 billion views to date. And while many were taking this opportunity to speak out about people abusing these medications who don’t meet the criteria for obesity, the popularity continued to surge. Ozempic became one of the most talked about drugs in 2023.

Insurance 105

Insurance Prescription Filling FDA Dosage 105

Pharmaceutical Technology

JANUARY 17, 2023

Bimagrumab is of interest in the obesity space as it is a first-in-class therapy for obesity. Bimagrumab is an activin receptor type 2B (ACVR2B or EC 2.7.11.30) antagonist that offers a unique mechanism of action within the obesity market. Mounjaro is anticipated to launch in the US later this year or by early 2024.

Hospitals 52

Hospitals 52

The Checkup by Singlecare

NOVEMBER 2, 2023

More people need treatment for obesity: The rise in obesity rates parallels the rise of GLP-1 prescriptions. The prevalence of obesity in the United States has increased from 30.5% The alarming increase in obesity rates heightens the need for effective weight management solutions. in 1999-2000 to 41.9% in 2017-2020.

Insurance 52

Insurance FDA Adverse Reactions Hospitals 52

The Checkup by Singlecare

AUGUST 31, 2023

If Mounjaro is prescribed for obesity, health insurance providers will not cover it. With a monthly price tag of $1,580, Mounjaro is no exception. The VA and Tricare classify Mounjaro as non-formulary, so a prescription will only be covered with prior authorization if certain criteria are met. mL of 5 mg/0.5

Insurance 98

Insurance Compounding Insurance Coverage Labelling 98

The Checkup by Singlecare

SEPTEMBER 7, 2023

While Mounjaro does not carry an approved indication for weight loss, it is commonly used off-label for this effect in prediabetic patients looking to avoid a diabetes diagnosis and obese patients looking to lose a significant amount of weight. All GLP-1 agonists today are injectable drugs except for Rybelsus, the only oral option.

Insurance 52

Insurance Insurance Coverage FDA Dosage 52

PharmD Live

JANUARY 25, 2022

Obesity is rising in the more sedentary aging population, an extra layer of risk for Medicare patients. Diabetes 2, low quality of life, cardiac-related illnesses, osteoarthritis, and more are caused or exacerbated by obesity. Eidenberg additionally received a Healthcare Management MBA from Walden University. Joseph Guglielmo, PharmD.

Adverse Reactions 52

Adverse Reactions Patient Care Communication Hospitals 52

The Checkup by Singlecare

JUNE 21, 2023

In fact, in the United States , 1 in 3 adults is overweight (defined as a body mass index, or BMI, between 25 and 25.99), and two in five are obese (defined as a BMI over 30). Being obese and overweight leads to an increased risk of serious health issues, including high cholesterol, hypertension, stroke, cancer, and death.

Insurance 98

Insurance FDA Compounding Compounding Pharmacies 98

Pharmaceutical Technology

NOVEMBER 30, 2022

In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. were obese, and 9.2%

Insurance 105

Insurance Labelling Communication FDA 105

Pharmaceutical Technology

NOVEMBER 30, 2022

In what’s being called a “medical bypass”, new anti-obesity drugs are almost matching efficacy rates in weight loss that have previously only been seen with weight loss surgeries. In October, the US FDA granted Eli Lilly’s Mounjaro (tirzepatide) a Fast Track designation for its use as a treatment for obesity. were obese, and 9.2%

Insurance 98

Insurance Labelling Communication FDA 98

Pharma Marketing Network

JUNE 8, 2020

I mean, you know, there has obviously been a lot of breakthrough biologics and different therapeutics like around cancers and things like that, that have high price tags because maybe they don’t have as big a market as you know, something’s wrong, you know blood pressure medication. So yeah, there is plenty to talk about there.

Health and Personal Care Stores 40

Health and Personal Care Stores Hospitals Mayo Clinic Specialty Pharmacies 40